Kisqali OverviewRibociclib (previously LEE 011) is an inhibitor of cyclin D1/CDK4 and CDK6, and is being studied as a treatment for drug-resistant cancers. It was developed by Novartis and Astex Pharmaceuticals. It was approved by the US FDA in March 2017 for use in combination with an aromatase inhibitor to treat some metastatic breast cancers. It will be marketed as Kisqali. Contents 1 Mechanism 2 Clinical trials 3 See also 4 References Mechanism For more details on this topic, see ...
Read more Kisqali Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Ribociclib
Recent Kisqali Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Tablet: 200mg
NDC Database Records for Kisqali: (3 results)Sorted by National Drug Code
- 0078-0860 Kisqali 200 mg Oral Tablet, Film Coated by Novartis Pharmaceuticals Corporation
- 0078-0867 Kisqali 200 mg Oral Tablet, Film Coated by Novartis Pharmaceuticals Corporation
- 0078-0874 Kisqali 200 mg Oral Tablet, Film Coated by Novartis Pharmaceuticals Corporation